التفاصيل البيبلوغرافية
| العنوان: |
MEK inhibition and immune responses in advanced melanoma. |
| المؤلفون: |
Dummer, Reinhard, Ramelyte, Egle, Schindler, Sabrina, Thürigen, Olaf, Levesque, Mitchell P., Koelblinger, Peter |
| المصدر: |
OncoImmunology; 2017, Vol. 6 Issue 8, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
MELANOMA, IMMUNE response, ANTINEOPLASTIC agents |
| مستخلص: |
phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy improved the outcome of binimetinib therapy. We discuss this finding in the context ofin vitroandin vivoeffects of MEK inhibition on immuno-critical pathways and interactions. [ABSTRACT FROM AUTHOR] |
|
Copyright of OncoImmunology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder